IQVIA vs Saama (2026)
Two sponsor side vendors selling agents into clinical development, at very different scales. IQVIA launched a unified agentic platform and marketplace in March 2026 spanning clinical, commercial and real world evidence work, names its infrastructure stack precisely, and has the most developed governance apparatus in this category. Saama is narrower and more specific, automating data quality review and query generation across more than fifteen hundred studies at over fifty sponsors, and it names its own autonomy level for its agents, which is a disclosure almost nothing here offers. Both should be asked which of their several relationships to your data governs which capability, because each is simultaneously a service provider, a data holder and a software vendor, and that ambiguity is where sponsor legal teams get stuck.
- The March 2026 agentic platform spans clinical, commercial and real world evidence operations with a marketplace, and the infrastructure stack is named with unusual precision.
- The governance apparatus is the most developed in this category and includes a concrete architectural control rather than a principles page.
- For a sponsor already working with the organisation across trial operations, the agents arrive inside an existing relationship.
- It names its own autonomy level for its agents, which almost nothing in this index does, so a buyer knows what the system decides on its own.
- Deployment is substantial and long standing across more than fifteen hundred studies at over fifty sponsors, so the platform has met real variety.
- Scope is bounded to sponsor side clinical development from study start through regulatory submission rather than spanning commercial operations too.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. IQVIA and Saama are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for IQVIA on any axis it scores. Set against Saama, IQVIA grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Saama its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against IQVIA, Saama grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose IQVIA or Saama?
On the axes where the AI Health Index separates them, IQVIA grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and AI Governance and Bias Disclosure, and Saama grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Saama leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do IQVIA and Saama differ most?
The widest separation the AI Health Index records between IQVIA and Saama is on Model Supply Chain Disclosure, where IQVIA grades B and Saama grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do IQVIA and Saama grade the same?
The AI Health Index grades IQVIA and Saama the same on several axes, including Model and Technology Transparency, Security Certifications and Trust Center and FDA and Regulatory Status. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have IQVIA and Saama not disclosed?
At the last review, at least one of IQVIA and Saama published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both stand in more than one relationship to sponsor data, as service provider, data holder and software vendor, and neither states plainly which relationship governs which capability, which is the first question a sponsor's legal team will ask. Neither publishes an attestation scoped specifically to the agent platform as distinct from the wider business. Saama publishes a governance framework with nothing measurable behind it and no security attestation. Ask both explicitly whether one sponsor's data improves models serving another, and get the answer in contract rather than in a meeting.